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Abstract  
 
Background: Secondary hyperparathyroidism (SHPT) in chronic kidney disease is 
associated with cardiovascular and bone pathology. Measures to achieve 
parathyroid hormone (PTH) target values and control biochemical abnormalities 
associated with SHPT require complex therapies, and severe SHPT often requires 
parathyroidectomy or the calcimimetic cinacalcet. In Australia, cinacalcet was 
publicly funded for dialysis patients from 2009 to 2015 when funding was withdrawn 
following publication of the EVOLVE study, which resulted in most patients on 
cinacalcet ceasing therapy. We examined the clinical and biochemical outcomes 
associated with this change at Australian renal centres. 
Methods: We conducted a retrospective study of dialysis patients who ceased 
cinacalcet after August 2015 in 11 Australian units. Clinical outcomes and changes 
in biochemical parameters were assessed over a 24- and 12-month period 
respectively from cessation of cinacalcet.  
Results: 228 patients were included (17.7% of all dialysis patients from the units). 
Patients were aged 63±15 years with 182 patients on haemodialysis and 46 on 
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peritoneal dialysis. Over 24 months following cessation of cinacalcet, we observed 
26 parathyroidectomies, 3 episodes of calciphylaxis, 8 fractures and 50 deaths. 
Seven patients recommenced cinacalcet, meeting criteria under a special access 
scheme. Biochemical changes from baseline to 12 months after cessation included 
increased levels of serum PTH from 54 (IQR 27-90) pmol/L to 85 (IQR 41-139) 
pmol/L (p<0.0001), serum calcium from 2.3±0.2mmol/L to 2.5±0.1mmol/L (p<0.0001) 
and alkaline phosphatase (ALP) from 123 (92-176) IU/L to 143 (102-197) IU/L 
(p<0.0001).  
Conclusion: Significant increases in serum PTH, calcium and ALP occurred over a 
12-month period following withdrawal of cinacalcet. Longer term follow-up will 
determine if these biochemical and therapeutic changes are associated with altered 
rates of parathyroidectomies and cardiovascular mortality and morbidity. 
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Introduction 
 
Secondary hyperparathyroidism (SHPT) begins early in the course of chronic kidney 
disease (CKD) and is characterized by progressive parathyroid gland hyperplasia, 
excessive parathyroid hormone (PTH) secretion and abnormalities in calcium and 
phosphate metabolism. As renal function declines SHPT becomes almost ubiquitous 
and results in bone and endocrine abnormalities, together with extra-osseous 
calcification. SHPT has been associated with left ventricular dysfunction (1), 
myocardial fibrosis (2), dyslipidemia (3), peripheral neuropathy (4) and anaemia as a 
result of reduced red blood cell survival and bone marrow fibrosis (5). SHPT is a 
significant component of the well-recognized broader clinical syndrome 
encompassing mineral, bone and cardiovascular abnormalities that develop as a 
complication of CKD - Chronic Kidney Disease Mineral and Bone Disorder (CKD-
MBD).  
 
Traditional management of SHPT is aimed at controlling phosphate by means of 
restricting intake, optimizing dialysis and administering phosphate binders, as well as 
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modulating calcium balance and suppressing PTH release with activated vitamin D. 
Despite traditional management, patients with severe and progressive disease may 
require surgical management with a parathyroidectomy. Although 
parathyroidectomies improve biochemical parameters and clinical symptoms related 
to severe SHPT, they are associated with an increased 30-day mortality and risk of 
re-hospitalization with hypocalcaemia (6). Surgical management also may not be 
suitable for older patients with complex co-morbidities, which encompasses a large 
proportion of dialysis patients in the Western world. In some cases, the effect of 
parathyroidectomy is also transient, with recurrence in up to 14% (7).  
 
The only oral calcimimetic available to date is cinacalcet which provides a medical 
alternative to parathyroidectomy and acts as a positive allosteric modulator of the 
calcium sensing receptor (CaSR) reducing PTH secretion. Cinacalcet reduces PTH 
(8-11) and, in patients on dialysis, cinacalcet plus low doses of activated vitamin D 
reduces progression of coronary artery calcification score volume when compared to 
higher activated vitamin D therapy (12). In Australia, government reimbursement for 
cinacalcet was introduced in 2009, but was contingent on proof of efficacy and cost-
effectiveness from the pivotal Effect of Cinacalcet on Cardiovascular Disease in 
Patients Undergoing Dialysis (EVOLVE) trial (13). 
 
Following publication of EVOLVE, which showed no change in the unadjusted 
composite primary end-point of cardiovascular mortality and morbidity in patients on 
cinacalcet, government reimbursement for cinacalcet in Australia was withdrawn in 
August 2015 due to the lack of evidence of cost-effectiveness. Secondary analyses 
of the study did report benefits, including reduced cardiovascular mortality in patients 
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over 65 years of age (14), a reduction in the risk of calciphylaxis (15) and possibly 
fracture risk (16). Globally, predictive Markov models were able to demonstrate cost 
effectiveness in Italy (17) and Japan (18), especially for patients unsuitable for 
parathyroidectomy. Economic analysis in Australia showed benefit in reducing 
parathyroidectomy rates, as well as clinical benefits in those over 65 years, however 
given financial feasibility was not met, funding of this medication was not continued. 
The hypothesis of our present study was that withdrawal of cinacalcet in dialysis 
patients with SHPT in Australia may be associated with changes to biochemical and 
clinical outcomes, including parathyroidectomy rates and prescribing practices. 
 
Methods 
 
Study design 
 
We performed a retrospective observational study involving maintenance dialysis 
patients who had ceased cinacalcet therapy after August 2015. The aim was to 
assess the impact on clinical outcomes and biochemical parameters of mineral 
metabolism after withdrawal from cinacalcet in patients on dialysis. The study 
protocol was approved by the local ethics committee at Melbourne Health (The 
Royal Melbourne Hospital). Reciprocal ethics and governance approval was 
arranged at each site involved in the study. 
 
Study Population 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Eleven nephrology units across Australia (The Royal Melbourne Hospital, Royal 
Hobart Hospital, Princess Alexandra Hospital, Sunshine Coast Hospital, Canberra 
Hospital, Westmead Hospital, Blacktown Hospital, Nepean Hospital, St Vincent’s 
Health, Sir Charles Gairdner Hospital and Western Health) participated in the study. 
There were no specific exclusion criteria. Each centre provided data regarding 
patient demographics, changes in prescription practices and biochemical changes 
over a 12-month period from August 2015. Mortality and morbidity data, including 
rates of parathyroidectomies, rates of clinically-evident vertebral or non-vertebral 
fractures, and episodes of calciphylaxis were collected at each centre over 24 
months following medication cessation.  
 
Study endpoints 
 
The primary endpoint was change in biochemical outcome measures over a 12-
month period. Patients were excluded from final analysis if they underwent a renal 
transplant, had a parathyroidectomy or restarted cinacalcet, via an industry-
sponsored special access scheme, within 12 months of withdrawal of the medication. 
Comparison analysis between deceased and non-deceased participants was 
performed to ensure demographics, clinical outcomes and biochemical 
characteristics were not confounded.  
 
Biomarker assessment 
 
Biochemical data was obtained from each nephrology unit. All hospitals measure 
intact PTH, although a variety of testing platforms for PTH are currently used by 
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pathology departments. All patients had measurements over the course of 12-month 
study period performed at the same centre and on the same platform which reduced 
intra-sample variability. There remains some variability between different intact PTH 
platforms currently available (19), however variability between different platforms 
used across units in different states was unavoidable. 
 
Statistical analysis 
 
All data are summarised and results reported as mean (+/-standard deviation [SD]) 
or median (inter-quartile range [IQR]) for continuous data and number (percentage, 
%) for categorical variables. Paired t-test and Wilcoxon signed-rank test were used 
for between group comparisons. Categorical variables were analyzed with Chi-
square test. Continuous variables were compared with one-way repeated measure 
ANOVA if normally distributed or with Freidman test if the distribution was skewed. 
Two-tailed P values <0.05 were considered statistically significant. All statistical 
analyses were performed using SPSS version 21.0 for Macintosh (SPSS, Chicago, 
IL). 
 
Results 
 
Demographics and clinical characteristics 
 
The study included 228 patients in whom cinacalcet had been ceased between 
August and December 2015. This represents 17.7% of dialysis patients across the 
11 units. Baseline characteristics are shown in Table 1. The mean age and median 
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time on dialysis were 6315 years and 5.7 (IQR 3-8) years respectively. Thirty-seven 
percent of patients had diabetes, 74% had a history of hypertension and 38% had a 
history of ischaemic heart disease.  
 
Clinical outcomes 
 
Over a 2-year period, 26 patients underwent parathyroidectomies, 19 of which 
occurred within the first 12-month period. There were three episodes of calciphylaxis, 
eight non-vertebral fractures and 50 deaths (26 in the first 12 months and 24 in the 
subsequent 12 months), with an annual overall mortality rate of 11.0%. Deceased 
patients were older, with a mean age of 69 11 years (p=0.005), however the 
median time on dialysis (6 [IQR3-7] years, p=0.9) and associated comorbidities 
including hypertension (p=0.70), diabetes (p=0.14) and ischaemic heart disease 
(p=0.14) were similar in both cohorts.  
 
Biochemical outcomes 
 
Thirty-five patients were excluded from 12-month analysis of biochemical changes 
and prescribing practices. Demographics and clinical features of this cohort are 
described in Table 2. Nineteen underwent parathyroidectomies, seven re-
commenced cinacalcet therapy, with access to medication via an industry-sponsored 
special access scheme, and seven received a kidney transplant.  
 
There was an increase in PTH from 54 pmol/L (27 -90 pmol/L) to 85 pmol/L (41 -139 
pmol/L) at 12 months (p<0.001), with the greatest change occurring by 6 months 
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(p<0.001) (Figure 1). Correspondingly, serum calcium increased from 2.300.2 
mmol/L to 2.500.1 mmol/L (p<0.001), and phosphate remained unchanged over the 
observation period (p=0.84).  There were 54 episodes of hypercalcaemia (serum 
corrected calcium > 2.6mmol/L) at 6 months, with 31 episodes occurring at 12 
months, this was significantly increased from 19 episodes of hypercalcaemia 
identified at baseline (p=0.002). There was an increase in alkaline phosphatase 
(ALP) from 123 IU/L (92-176 IU/L) to 143 IU/L (102-197 IU/L) at 12 months 
(p<0.001). Inflammatory markers, including C-reactive protein (CRP) and ferritin 
remained stable over 12-months, and there was a fall in serum albumin from 35.5+/-
4.6 g/L to 34.5+/-4.5 g/L, p=0.01. Table 3 summarizes baseline, 6-month and 12-
month values for biochemical outcomes in the study cohort. 
 
Changes in prescribing practices 
 
The median daily dose of cinacalcet prior to medication cessation was 30mg [30-
60mg]. At baseline, 38% of patients (n=74) were on a calcium-based phosphate 
binder and 66% (n=127) on a non-calcium based phosphate binder. Twenty-six 
percent (n=56) were on two phosphate binders and 21% percent (n=46) were not 
taking any phosphate binder. At baseline, active vitamin D use was high at 65% 
(n=125) and 26% (n=51) were on nutritional vitamin D. By 12 months following 
cinacalcet withdrawal, phosphate binder use was significantly reduced, with 29% 
(n=52, p=0.01) on a calcium based binder and 50% (n=97, p=0.008) on a non-
calcium based binder. Active vitamin D use also reduced by 12 months to 48% 
(n=93), p=0.03. However, of the patients who remained on active vitamin D their 
dose was increased from 1.6+/-0.8 mcg/week to 2.2+/-1.3 mcg/week (p=0.005). 
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There was no change in cholecalciferol administration (p=0.23). Table 4 describes 
prescribing practice changes following cinacalcet withdrawal. There were no 
significant changes in prescribing practice results with or without death censoring of 
data. There was no change to time on dialysis following cinacalcet withdrawal or any 
change in dialysis modality amongst individuals in the cohort. 
 
Discussion 
 
Our study of 228 dialysis patients from 11 nephrology centres across Australia is the 
first to show clinical and biochemical outcomes of cinacalcet withdrawal in a large 
cohort. We report that cinacalcet cessation, when previously used for the 
management of SHPT, was not associated with increased clinical outcomes after 2 
years from withdrawal when compared to reported outcomes in the Australian 
dialysis population, apart from the rate of parathyroidectomy. Associated biochemical 
changes however included a rise in PTH, calcium and ALP, no corresponding 
change in serum phosphate, and a fall in serum albumin in the first 12 months after 
medication withdrawal.  
 
Following cinacalcet withdrawal, there was a statistically significant increase in ALP, 
which may represent increased bone turnover. Recent publications suggest 
cinacalcet use may improve bone metabolism and is associated with reduced bone 
turnover markers including bone specific ALP, osteocalcin and beta-crosslaps (20). 
Cunningham et al (21) reported reduced parathyroidectomy, fracture and 
cardiovascular hospitalization rates with cinacalcet use in a combined analysis of 
four clinical trials, and secondary analysis of the EVOLVE trial identified a trend 
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towards reduced rates of fractures with cinacalcet use, particularly in older patients 
(16). The fracture rate in our cohort was relatively small with only eight clinically-
evident fractures during the study period, although the incidence of fracture may 
have been under-reported by units. Fractures seen in primary care settings and 
asymptomatic vertebral fractures may have potentially not been included.  
 
With regards to clinical outcomes, 11% of patients underwent a parathyroidectomy 
within 2 years of medication cessation, equating to an 86/1000-person year 
parathyroidectomy rate. There was no observed increase in calciphylaxis, with three 
episodes identified in the cohort over the 24-month study period. The mortality rate 
of the cohort was 11% per year which is comparable to current published Australian 
dialysis mortality data for patients in a similar age group (22). As vascular 
calcification and associated cardiovascular mortality and morbidity related to SHPT 
may take many years to develop, this cohort requires further follow up to identify if 
there are potentially longer-term associations with cinacalcet withdrawal. 
 
Parathyroidectomy rates are not currently recorded in the Australian and New 
Zealand Dialysis and Transplant registry (ANZDATA), unlike other parameters 
including cardiovascular disease and cancer. Therefore, this study is limited in being 
able to identify increased rates of parathyroidectomy since reimbursement of 
cinacalcet ceased. Certainly, within one centre at The Royal Melbourne Hospital, we 
have seen a 69% increase in the rate of parathyroidectomies since 2015. Data from 
Canada following the public formulary listing of cinacalcet showed a significant 
decrease in parathyroidectomy rates from 11.4/1000 persons-years to 3.6/1000 (23).  
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Multiple studies have highlighted the short-term risks associated with 
parathyroidectomies in patients on dialysis (6, 24). A review of clinical outcomes 
following parathyroidectomy using United States Renal Data System (USRDS) data, 
demonstrated a 2% 30-day mortality and 23.8% re-hospitalization rate following 
surgery, together with a 39% increase in hospitalization rate in the year following 
parathyroidectomy (24). Long term mortality in younger dialysis patients may be 
better with parathyroidectomy compared with medical management (25), however it 
is difficult to generalize this potential benefit to our study cohort, given the average 
age in our study cohort was 63 years, with a higher percentage of co-morbidities 
including diabetes and ischaemic heart disease.  
 
Patient preference in regards to treatment of SHPT with cinacalcet versus 
parathyroidectomy has not been assessed to our knowledge. The impact on quality 
of life with parathyroidectomy versus cinacalcet has recently been examined in a 
systematic review of eight studies (26). Although a direct comparison between the 
two interventions could not be made, parathyroidectomy was associated with 
improvement in short and long-term quality of life, including improvement in itch, joint 
pain and muscle weakness, whereas no difference was seen in quality of life with the 
use of cinacalcet. It is possible that reduction in PTH with surgery compared to 
medical suppression is more beneficial, however it is unlikely that a head-to-head 
comparison will ever be undertaken. 
 
Reduced use of activated vitamin D from 65% to 48% was not unexpected, because 
use of cinacalcet allows clinicians to target lower PTH values by enabling increased 
dosing with activated vitamin D with a reduced risk of hypercalcaemia. Nevertheless, 
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there was no associated increase in serum phosphate over a 12-month period after 
cinacalcet withdrawal, suggesting that cinacalcet alone was insufficient to overcome 
the biochemical effects of hyperphosphataemia resulting from increased calcitriol 
use. In fact, one consideration is whether cinacalcet availability emphasizes the 
potential to achieve lower PTH values leading to higher calcitriol and phosphate 
binder requirements. Since oversuppression of PTH and higher phosphate binder 
use may have adverse consequences, particularly when calcium-based binders are 
used, the question arises as to longer term patient-level benefits of more complex 
combined therapies that include cinacalcet.  
 
Limitations of our study include its retrospective observational nature and therefore 
we do not have a control group to compare identified clinical and biochemical 
changes. Comparing mortality and morbidity data in our cohort to published data in 
the general Australian dialysis population involves selection bias as we have studied 
a cohort of individuals previously prescribed cinacalcet based on clinical indication 
as determined by their treating clinicians. Also, not all units across Australia were 
involved in data collection and there was a short duration of follow up. Furthermore, 
we were unable to comprehensively collect all morbidity outcomes, including fracture 
rates and types of cardiovascular events, as well as changes in dosing of phosphate 
binders in all study participants, given the study’s retrospective nature. Another 
limitation is that given the variability between different PTH analysis platforms it is 
possible we have over or under-estimated the change in PTH over the study period. 
Strengths of our study include a large data set across 11 Australian centres with 
varying geographical locations, which provides a unique insight into the effects of 
cinacalcet withdrawal, perhaps not possible in many another countries. We have 
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also collected comprehensive national biochemical parameters and 
parathyroidectomy rates in Australia in the era following withdrawal of cinacalcet 
reimbursement. 
 
In conclusion, for patients in the Australian dialysis population who withdrew from 
cinacalcet therapy, median values of PTH exceeded the Kidney Disease Improving 
Global Outcomes (KDIGO) CKD-MBD guidelines suggested upper target range of 9-
times the upper range of the PTH assay, calcium and ALP values rose, and there 
was no change in serum phosphate. The parathyroidectomy rate was 86/1000 
patient-years over the first 24 months from withdrawal. Longer term follow-up will 
allow greater insight into associated future cardiovascular morbidity, mortality and 
fracture rates. 
Authorship Page: 
 
Authors 
 
Ruderman I, Holt S and Nigel T contributed to the conception, critical appraisal of 
paper and drafting of the work. 
 
All authors contributed to the writing of the manuscript and approved the final copy of 
paper. 
 
Disclosures 
IR declares she has no competing interests. NDT and GJE have received honoraria, 
travel support and research funding from Amgen, Shire and Sanofi. SGH has 
research funding, honoraria and travel support from Amgen, Astra-Zenica, Baxter 
and Sanofi. RK has received honoraria and travel support from Shire and Amgen. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
 
References 
 
1. London GM, De Vernejoul MC, Fabiani F, Marchais SJ, Guerin AP, Metivier F, et al. 
Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney 
international. 1987;32(6):900-7. 
2. Ketteler M, Gross M-L, Ritz E. Calcification and cardiovascular problems in renal 
failure. Kidney international.67:S120-S7. 
3. Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely 
affects lipid metabolism in chronic renal failure. Kidney international. 1990;37(3):854-8. 
4. Avram  MM, Feinfeld  DA, Huatuco  AH. Search for the Uremic Toxin. New England 
Journal of Medicine. 1978;298(18):1000-3. 
5. Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. Seminars in dialysis. 
2009;22(4):363-8. 
6. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, et al. 
Survival following parathyroidectomy among United States dialysis patients. Kidney 
international. 2004;66(5):2010-6. 
7. Agha A, Loss M, Schlitt HJ, Scherer MN. Recurrence of secondary 
hyperparathyroidism in patients after total parathyroidectomy with autotransplantation: 
technical and therapeutic aspects. European archives of oto-rhino-laryngology : official 
journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : 
affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 
2012;269(5):1519-25. 
8. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. 
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. The New 
England journal of medicine. 2004;350(15):1516-25. 
9. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The 
calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in 
secondary hyperparathyroidism. Kidney international. 2003;63(1):248-54. 
10. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The 
calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-
stage renal disease. Journal of the American Society of Nephrology : JASN. 2003;14(3):575-
83. 
11. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet 
HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in 
hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal 
of the American Society of Nephrology : JASN. 2005;16(3):800-7. 
12. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE 
study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on 
vascular calcification in patients on hemodialysis. Nephrology, dialysis, transplantation : 
official publication of the European Dialysis and Transplant Association - European Renal 
Association. 2011;26(4):1327-39. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
13. Investigators TET. Effect of Cinacalcet on Cardiovascular Disease in Patients 
Undergoing Dialysis. New England Journal of Medicine. 2012;367(26):2482-94. 
14. Parfrey PS, Drueke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, et al. The 
Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of 
Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc 
Nephrol. 2015;10(5):791-9. 
15. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on 
Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. 
Clin J Am Soc Nephrol. 2015;10(5):800-7. 
16. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, et al. Effects 
of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. 
Journal of the American Society of Nephrology : JASN. 2015;26(6):1466-75. 
17. Eandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G. Economic Evaluation of 
Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy. 
PharmacoEconomics. 2010;28(11):1041-54. 
18. Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, et al. Cost-
effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary 
hyperparathyroidism in Japan. American journal of kidney diseases : the official journal of 
the National Kidney Foundation. 2012;60(2):262-71. 
19. Eddington H, Hudson JE, Oliver RL, Fraser WD, Hutchison AJ, Kalra PA. Variability in 
parathyroid hormone assays confounds clinical practice in chronic kidney disease patients. 
Annals of clinical biochemistry. 2014;51(Pt 2):228-36. 
20. Yuan F, Chen X, Wang C, Li Z, Liu H. Effect of Cinacalcet Combined with Calcitriol on 
the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe 
Secondary Hyperparathyroidism. Blood Purification. 2018;45(1-3):73-8. 
21. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the 
calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of 
life in secondary hyperparathyroidism. Kidney international. 2005;68(4):1793-800. 
22.  
ANZDATA Registry. 39th Report, Chapter 3: Mortality in End Stage Kidney Disease. Australia 
and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2017. Available at: 
http://www.anzdata.org.au. 
23. Lafrance J-P, Cardinal H, Leblanc M, Madore F, Pichette V, Roy L, et al. Effect of 
cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC 
Nephrology. 2013;14:100-. 
24. Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al. Clinical outcomes 
after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc 
Nephrol. 2015;10(1):90-7. 
25. Moldovan D, Racasan S, Kacso IM, Rusu C, Potra A, Bondor C, et al. Survival after 
parathyroidectomy in chronic hemodialysis patients with severe secondary 
hyperparathyroidism. International urology and nephrology. 2015;47(11):1871-7. 
26. van der Plas WY, Dulfer RR, Engelsman AF, Vogt L, de Borst MH, van Ginhoven TM, et 
al. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage 
renal disease-related hyperparathyroidism: a systematic review. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and Transplant Association - 
European Renal Association. 2017;32(11):1902-8. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
 
Table 1: Patient demographics and clinical characteristics  
 
Demographic Cinacalcet withdrawal patients 
(n=228) 
Age, years 63 +/- 15 
Gender (male) 138 (60%) 
Dialysis modality (haemodialysis) 182 (80%) 
Time on dialysis, years 5.7 [3-8] 
Diabetes 84 (37%) 
Hypertension 170 (74%) 
Ischaemic heart disease 86 (38%) 
Peripheral vascular disease  26 (11%) 
Events during follow up (24 months)  
Parathyroidectomy 26 (11%) 
Non-vertebral fractures 8 (3.5%) 
Calciphylaxis 3 (1.3%) 
Deaths  50 (23%) 
 
Data presented as number (percent), mean +/- standard deviation or median [interquartile 
range] 
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Table 2: Demographics and clinical characteristics of patients who underwent 
parathyroidectomy and renal transplantation or restarted cinacalcet during the study 
period 
 
Demographic Patients excluded from final analysis 
(n=35) 
Age, years 55 +/- 13 
Gender (male) 20 (57%) 
Dialysis modality (haemodialysis) 22 (63%) 
Time on dialysis, years 4 [2-7] 
Diabetes 9 (26%) 
Hypertension 28 (80%) 
Ischaemic heart disease 10 (28%) 
Peripheral vascular disease  3 (8%) 
Baseline medications  
Calcium-based phosphate binder use  8 (23%) 
Non-calcium-based phosphate binder 
use  
23 (66%) 
Active vitamin D use  20 (57%) 
Nutritional vitamin D use  7 (20%) 
Erythropoietin-stimulating agent use  20 (57%) 
 
Data presented as number (percent), mean +/- standard deviation or median [interquartile 
range] 
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Table 3: Biochemical changes over 12-month period following cinacalcet withdrawal  
 
Biochemistry  Baseline 
(n=193) 
6 months 
(n=177) 
12 months 
(n=167) 
p value 
PTH, pmol/L 54 [27-90] 83 [40-115] 85 [41-139] p<0.0001 
Calcium, mmol/L 2.3 +/- 0.2 2.5 +/- 0.2 2.5 +/- 0.1 p<0.0001 
Phosphate, mmol/L 1.6 +/- 0.58 1.6 +/- 0.47 1.6 +/- 0.57 p=0.84 
ALP, IU/L 123 [92-176] 134 [101-184] 143 [102-197] p<0.0001 
Albumin, g/L 35.5 +/- 4.6 35.1 +/- 5.0 34.5 +/- 4.5 p=0.010 
CRP, mg/L 7 [3-16] 7 [3-19] 9.5 [4-29] p=0.09 
Ferritin, ug/L 312 [187-496] 309 [159-524] 367 [180-540] p=0.08 
Haemoglobin, g/L 110 +/- 14 111 +/- 14 110 +/- 117 p=0.67 
Bicarbonate, mmol/L 23 +/- 3 22 +/- 3 23 +/- 3 p=0.42 
 
Data presented as mean +/- standard deviation or median [interquartile range] 
Abbreviations: ALP, alkaline phosphatase; CRP, C-reactive protein; PTH, parathyroid hormone 
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Table 4: Changes in prescribing practices 
 
Medications  
 (n=193) 
Baseline 6 months 12 months P value 
Calcium-based phosphate 
binders  
74 (38%) 49 (25%) 52 (29%) p=0.01 
Non-calcium-based phosphate 
binders 
127 (66%) 112 (58%) 97 (50%) p=0.008 
Active vitamin D  125 (65%) 112 (58%) 93 (48%) p=0.03 
Nutritional vitamin D  51 (26%) 33 (17%) 37 (19%) p=0.23 
Erythropoietin-stimulating 
agent use  
127 (66%) 116 (60%) 100 (52%) p=0.09 
 
Data presented as number (percent) 
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Legends to figures: 
 
Figure 1: Changes in biochemical mineral markers over 12 months following 
cinacalcet withdrawal. Changes in (a) parathyroid hormone, (b) calcium, (c) 
phosphate and (d) alkaline phosphatase over a 12-month period summarized in line 
graph (median, lower and upper quartile). 
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